Scientists test supercharged immune cells against tough prostate cancer
NCT ID NCT03089203
Summary
This early-stage study is testing a new type of cell therapy for men with advanced prostate cancer that has stopped responding to standard hormone treatments. Doctors take a patient's own immune cells, genetically modify them in a lab to better target prostate cancer cells and resist being shut down by the tumor, then infuse them back into the patient. The main goals are to see if this process is safe and feasible, and to get an early look at whether it can shrink tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
Conditions
Explore the condition pages connected to this study.